RBC Capital raised the firm’s price target on Exact Sciences (EXAS) to $54 from $52 and keeps a Sector Perform rating on the shares after its Q1 results. The quarter has ushered the launch of Cologuard Plus and Oncodetect, keeping successful products center to the FY25 story, the analyst tells investors in a research note. The company’s pipeline updates like the BLUE-C readout in Summer of 2025 and second half’s CancerGuard launch provide key catalysts through the year, RBC adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $72 from $69 at Baird
- Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
- Exact Sciences price target raised to $75 from $55 at Barclays
- Exact Sciences Reports Strong Q1 2025 Results
- Closing Bell Movers: Apple and Amazon slip after earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue